Key facts
- It has raised $22.4M; the latest was IPO in Aug 2024.
- Notable investors include Tech Incubator Program for Startup, KB Investment, Mirae Asset Capital, SBVA, KDB Capital — 8 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 8 names
- ·Watchlist + deal alerts for Baropharm
- ·The full record, as it builds
Funding rounds
No funding rounds for Baropharm are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Baropharm
Developer of a pharmacy management platform designed to streamline pharmaceutical operations. The company's platform offers wholesale sites into a single integrated system, enabling pharmacies to efficiently order medicines from one location, improving operational efficiency and reducing complexity.
- Sector
- Healthcare
- HQ
- Seoul, South Korea
- Founded
- 2019
- Employees
- 51
- Website
- baropharm.com/
- Ownership
- Privately Held (backing)
Baropharm doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Baropharm shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Baropharm in its N-PORT filings yet. We sweep new filings monthly.